Allogene Therapeutics’ ALPHA Study: A Promising Update in CAR T Cell Therapy

Allogene Therapeutics (ALLO) announced an update on their ongoing clinical study.

The ALPHA study, officially titled A Single-Arm, Open-Label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR T Cell Therapy, And ALLO-647, An Anti-CD52 Monoclonal Antibody, in Patients With Relapsed/Refractory Large B-Cell Lymphoma or Follicular Lymphoma, aims to assess the safety and efficacy of ALLO-501 in treating adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma. This study is significant as it explores innovative therapies for challenging lymphoma cases.

The intervention involves ALLO-501, a genetic CAR T cell therapy targeting CD19, and ALLO-647, a biological monoclonal antibody targeting CD52. These treatments are designed to enhance the immune system’s ability to fight cancer cells.

The study follows an interventional design with a single-group assignment. There is no masking, and the primary purpose is treatment. This straightforward design allows for direct observation of the treatment effects.

Key dates for the study include its start on April 4, 2019, and the last update on November 3, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates on its findings.

The completion of this study could have significant market implications, potentially boosting Allogene Therapeutics’ stock performance and investor confidence. As the company advances in the competitive field of CAR T cell therapies, positive outcomes could position it favorably against competitors.

The study is ongoing, with further details available on the ClinicalTrials portal.

To learn more about ALLO’s potential, visit the Allogene Therapeutics drug pipeline page.